3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue-Reference-Cited by-同舟云学术

3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue

Published:2012-02 Issue:1 Volume:44 Page:1-6
ISSN:0145-479X
Container-title:Journal of Bioenergetics and Biomembranes
language:en
Short-container-title:J Bioenerg Biomembr

Author:

Pedersen Peter L.

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s10863-012-9425-4.pdf

Reference33 articles.

1. Bustamante E, Pedersen PL (1977) Proc. Natl Acad Sci (USA) 74:3735–3739

2. Bustamante E, Morris HP, Pedersen PL (1981) J Biol Chem 256:8699–8704

3. Cardaci S, Desideri E, Ciriolo R (2012) J Bioenerg Biomemb 44:17–29

4. Davidescu M, Sciaccaluga M, Maccchioni L, Agelina R, Lopalco P, Rambotti MG, Roberti R, Corcelli A, Castigli E, Corazzi L (2012) J Bioenerg Biomemb 44:51–60

5. El Sayed SM, Abou El-Magd RM, Shishido Y, Chung SP, Diem TH, Sakai T, Watanabe H Kagami S, Fukui K (2012) J Bioenerg Biomemb 44:51–60

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The novel family of Warbicin® compounds inhibits glucose uptake both in yeast and human cells and restrains cancer cell proliferation;Frontiers in Oncology;2024-08-22

2. Derivatization of Abietane Acids by Peptide-like Substituents Leads to Submicromolar Cytotoxicity at NCI-60 Panel;Molecules;2024-07-27

3. 3-bromopyruvate induces morphological alteration and may initiate programmed cell death in Cryptococcus neoformans cells;Archives of Microbiology;2024-03-12

4. Succinate metabolism: a promising therapeutic target for inflammation, ischemia/reperfusion injury and cancer;Frontiers in Cell and Developmental Biology;2023-09-22

5. Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma;Cancer Research;2023-09-11